Slanix Paul Alex insider trades: ProMIS Neurosciences (PMN) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Slanix reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | PMN | ↑ Buy | 700,741 | $12.13 | $8.5M | Indirect | Feb 5, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PMN insiders
Open-market trades in the last 12 months
About Slanix Paul Alex's insider trades
Slanix Paul Alex is a director at ProMIS Neurosciences (PMN). Since Feb 3, 2026, Slanix has reported 1 open-market purchase worth $8.5M and no sales on SEC Form 4. In the last 12 months: 1 buy ($8.5M).
Their filings also include grants and awards (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PMN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.